April 11th 2024
The FDA’s fast track designation of LYT-200 in this population is supported by an ongoing phase 1/2 clinical trial.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Updated Findings Confirm Nivolumab OS Benefit in SCCHN
April 18th 2018Patients with metastatic or recurrent squamous cell carcinoma of the head and neck experienced a 32% reduction in the risk of death compared with investigator's choice of therapy, according to updated findings with a minimum of 2 years of follow-up from the phase III CheckMate-141 study.
Read More
FDA Places Hold on Axalimogene Filolisbac Plus Durvalumab Trial in Cervical, Head and Neck Cancer
March 14th 2018The FDA has placed a clinical hold on a phase I/II study of axalimogene filolisbac and durvalumab, according to an announcement by Advaxis, the manufacturer of axalimogene filolisbac, in a quarterly earnings report.The study is evaluating the combination in patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck squamous cell carcinoma.
Read More
Jean Kozempel to Receive 2017 Oncology Section President's Award
February 27th 2018The American Physical Therapy Association has selected Jean Kozempel, PT, DPT, MS, as the recipient of the 2017 Oncology Section President’s Award. This award honors physical therapists who are proving themselves to be pioneers in the oncology field.
Read More